{"id":91025,"date":"2022-08-25T12:45:50","date_gmt":"2022-08-25T16:45:50","guid":{"rendered":"https:\/\/rarediseases.org\/upcoming-rare-disease-workshop-focuses-on-the-importance-of-data-sharing-in-drug-development\/"},"modified":"2025-12-22T14:15:24","modified_gmt":"2025-12-22T19:15:24","slug":"upcoming-rare-disease-workshop-focuses-on-the-importance-of-data-sharing-in-drug-development","status":"publish","type":"post","link":"https:\/\/rarediseases.org\/es\/upcoming-rare-disease-workshop-focuses-on-the-importance-of-data-sharing-in-drug-development\/","title":{"rendered":"Upcoming Rare Disease Workshop Focuses on the Importance of Data Sharing in Drug Development"},"content":{"rendered":"

C-Path, NORD and FDA to host annual workshop September 13-14 to highlight the impact of their innovative data and analytics platform on rare disease drug development<\/span><\/i>\u00a0<\/span><\/h3>\n

TUCSON, Ariz. and WASHINGTON, DC, <\/strong>August 25, 2022 \u2014 The Rare Disease Cures Accelerator-Data and Analytics Platform initiative (RDCA-DAP<\/a>\u00ae) will host its in-person annual workshop on September 13 and 14 at the Westin Crystal City<\/a>. RDCA-DAP is funded by the US Food and Drug Administration (FDA), with the goal of transforming rare disease data into solutions to accelerate the development of therapies across rare diseases.<\/p>\n

The 1.5-day workshop will include a keynote address by Theresa Mullin<\/strong>, Ph.D., Associate Director for Strategic Initiatives, FDA, Center for Drug Evaluation and Research (CDER), and feature other key speakers and panelists from FDA, industry, academia and patient representatives. Included on the agenda are case studies shared by users of the platform, sessions covering critical topics on the impact of RDCA-DAP on accelerating drug development for rare diseases, as well as active discussions around data privacy and standards, and much more. A key objective of the workshop is to continue to energize the rare disease community to lead the way in actionable data sharing to accelerate medical product development for patients in need.<\/p>\n

RDCA-DAP was created through a partnership between Critical Path Institute<\/a> (C-Path), the National Organization for Rare Disorders<\/a> (NORD\u00ae) and the FDA,<\/a> and has grown to include collaborations between a variety of stakeholders throughout the rare disease community. The platform serves as a centralized and standardized infrastructure to host and share data, to support and accelerate rare disease innovation.<\/p>\n

Attendees of the in-person workshop will have the opportunity to explore:<\/p>\n